Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in mileston
Atomwise and Hansoh Pharma have announced an artificial intelligence (AI) drug discovery deal that could be worth $1.5 billion, the largest US-China collaboration in the field.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
